VIVUS Inc. (NASDAQ: VVUS) is soaring on what is already exponential volume. The company’s interim update showed that patients taking Qnexa reduced their weight by up to 14.7% on average in one trial, and the drug also showed improvement in blood pressure and diabetes symptoms and risk factors. Vivus’ second study showed an average weight loss of about 13.2%. As far as how this compares to placebo, patients taking placebo lost less than 3% of their weight. As of 8:38 AM EST we have seen a gain of 50% at $10.33 and we have seen 3.6 million shares trade hands. Average volume is only about 750,000 shares and the prior 52-week high was $9.00. This will be a monster volume day for VIVUS. Be advised, this one does have call and put options on it. -JON OGG
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment